NASDAQ$CCCC
C4 Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
C4 Therapeutics reported its financial results for the second quarter ended June 30, 2025, with collaboration revenue and continued net losses.
C4 Therapeutics generated $6.5 million in revenue from its collaboration agreements during Q2 2025. The company reported a net loss of $26.0 million and an operating loss of $28.5 million while advancing its targeted protein degradation programs. Cash and cash equivalents stood at $78.2 million with additional marketable securities supporting operations.
- Q2 2025 collaboration revenue totaled $6.5 million, led by contributions from the MKDG and Roche agreements.
- Net loss for the quarter was $26.0 million, with R&D expenses at $26.2 million reflecting ongoing clinical development.
- Cash position remained solid at $78.2 million alongside $136.4 million in current marketable securities.
- Weighted average shares outstanding were approximately 71.0 million, resulting in a basic and diluted EPS of $(0.37).
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$6.46M
Revenue by segment
C4 Therapeutics · $6.46M total across 4 segments · Q2 2025
- MKDG Agreement$3.43M—53.0%
- Roche Agreement$1.93M—29.9%
- Merck Agreement$1.05M—16.2%
- Betta Agreement$54K—0.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+2.2%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+30.9%
Q2 2025
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q2 2025 | +30.9% | — | — | |
| Q1 2026 | +0.0% | +13.0% | +22.2% | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro